Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motavizumab biosimilar

Next Previous
Search
Drug Profile

Motavizumab biosimilar

Alternative Names: 3rd-generation anti-RSV MAb - AstraZeneca ; MEDI-557; Mota-YTE; Motavizumab-YTE; RSV-YTE

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 20 Jul 2017 MedImmune terminates a phase I trial for Respiratory syncytial virus infections in United Kingdom as it was determined to not be feasible to complete enrolment and the study within the required timeline and budget (IV) (NCT01475305)
  • 30 Jun 2013 Discontinued - Phase-I for Respiratory syncytial virus infections in USA and United Kingdom (IV)
  • 01 Apr 2013 MedImmune completes a phase I trial in healthy volunteers in the United Kingdom (NCT01475305)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top